Backgrounds/Aims: Pancreatic cancer is one of the most fatal human malignancies with poor prognosis, despite advances in therapy. Here, we evaluated the potential role of collagen type VI 3 chain (COL6A3) as a non-invasive biomarker for pancreatic adenocarcinoma. Methods: In this study, we investigated immunohistochemically the expression of COL6A3 in 30 patients with resectable pancreatic adenocarcinoma by immunohistochemistry in a tissue sample of the cancer and a tissue sample of normal pancreas for each patient. Also, we looked for associations between COL6A3 and other prognostic factors of pancreatic cancer. Results: All of the pancreatic cancer tissue samples revealed in different ranges of intensity from weak (+1) in 16.67%, moderate (+2) in 50%, to strongly positive (+3) in 33.33% staining for COL6A3. We found no moderate or strongly positive staining in normal pancreatic tissue. There was only weak positive staining in 23 samples (76.67%) and 7 (23.30%) were negative. Also, there was significant correlation between COL6A3 moderate and strongly expression and negative prognostic factors for pancreatic cancer.
INTRODUCTION
Pancreatic cancer is the third leading cause of cancer-related death and by 2030, it will be the second. The five-year survival rate for pancreatic cancer is reported at 8%, which is the lowest among many other common types of cancer. 1 However, pancreatic cancer is difficult to diagnose early and more than 80% of pancreatic cancers are locally advanced or metastatic at the time of diagnosis. fibrin. 4 The interactions between cancer cells and the microenvironment are complicated, as the stroma elements can provide either a support or a barrier for tumor growth or metastasis. Collagen is by far the most abundant and well-characterized component of the extracellular matrix in pancreatic cancer. 5 Currently, 28 different types of collagen have been described in the extracellular matrix in the pancreas. Collagen type VI is abundantly present in pancreas and it is the predominant constituent subtype, immediately surrounding islets in the pancreas. 6 Type VI collagen is structured as a trimer composed of three different alpha chains: alpha-1(VI), alpha-2(VI), and alpha-3(VI). It is now clear that type VI collagen has a vital role and can suppress apoptosis and oxidative damage, and enhance cell growth. 7, 8 Many recent studies have shown the overexpression of COL6A3 in many types of cancer, which is also associated with poor prognosis in many of them, such as colon, prostate and lung cancer. [9] [10] [11] However, there are few studies in the literature that have investigated the association of COL6A3 with pancreatic cancer.
The goal of this study was to investigate the expression of COL6A3 in pancreatic cancer adenocarcinoma and to compare it with the expression in the adjacent sections of pancreas where there were no cancer lesions. Furthermore, the prognostic value of COL6A3 was evaluated by comparing the expression of COL6A3 with clinicopathological prognostic factors for pancreatic cancer in these patients. 12 We also evaluated the lymph node ratio (LNR) by dividing the number of the positive lymph nodes with the number of all lymph nodes that were examined, the modified Glasgow prognostic score (mGPS) which incorporates the C-reactive protein and albumin values, the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR), and the lymphocyte/ monocyte ratio (LMR) for each patient.
MATERIALS AND METHODS

Sample collections and patients' characteristics
Immunochemistry
Immunostaining for COL6A3 was performed on individual formalin-fixed, paraffin-embedded pancreatic adenocarcinoma and healthy pancreatic tissue sections using mouse polyclonal antibody raised against the COL6A3 
Immunohistochemistry analysis
Statistical analysis
RESULTS
Study patients' characteristics
Samples were collected from 30 patients with pancreatic adenocarcinoma. The median age was 68.2 (44-86) patients. The clinicopathologic characteristics of the patients in this study are summarized in Table 1 . to be significant prognostic factors of the disease. [19] [20] [21] [22] Nevertheless, the number of patients alive at 5 years makes these prognostic variables only marginally influential.
Expression of COL6A3 protein
COL6A3 expression is associated with prognostic factors of pancreatic cancer
Therefore, it is important to understand the intrinsic properties of the development and the progression of the pancreatic cancer and to identify more accurate prognostic factors for more effective therapies.
The COL6A3 is an extracellular matrix protein, which is usually found in most connective tissues, including muscle, skin, tendon, and vessels. Recently, many studies revealed the important role of COL6A3 in the diagnosis and prognosis of colorectal, lung and prostate cancer. In summary, our results demonstrate that COL6A3 is overexpressed in pancreatic cancer stroma, suggesting that COL6A3 is involved in the progress of pancreatic cancer.
Also, COL6A3 was associated with negative prognostic factors of the disease, indicating that it could be a useful prognostic factor for pancreatic adenocarcinoma. In order to verify these results, a larger sample size and more in-depth analyses will be needed.
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